Cynthia H. Seow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cynthia H. Seow has a total of 483 co-authors. Here are the top co-authors by number of shared publications:
- Gilaad G. Kaplan
Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Canada
23 shared publications Remo Panaccione
Inflammatory Bowel Disease Unit, Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada
18 shared publications- Eric I. Benchimol
Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids), Toronto, Canada; ICES, Toronto, Canada; Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children (SickKids), Toronto, Canada; Department of Paediatrics, University of Toronto, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
15 shared publications - Christopher Ma
Division of Gastroenterology & Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary , Calgary, Alberta
13 shared publications - Geoffrey Christopher Nguyen
Department of Medicine, Mount Sinai Hospital Centre for Inflammatory Bowel Disease, University of Toronto, Toronto, Canada
13 shared publications - Remo Panaccione
Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary , Calgary, Alberta
13 shared publications
Latest Publications
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Comparative Real-World Effectiveness of Biologic Therapies for Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
BACKGROUND: Postoperative recurrence is common after ileocolonic resection for Crohn's disease (CD). Comparative effectiveness data for advanced treatments for preventing recurrence are limited. METHODS: We conducted a population-based retrospective cohort study of adults with CD undergoing ileocolonic resection with primary anastomosis in the Calgary Health Zone, Canada (2016–2020). The primary outcome was endoscopic recurrence within 18 months, assessed using the modified Rutgeerts score as an ordinal endpoint. High-risk recurrence (modified Rutgeerts score ≥ i2b) was evaluated as a secondary outcome. Propensity scores were estimated using established clinical risk factors, and inverse probability of treatment weighting targeting the average treatment effect among treated patients was applied to ordinal and logistic regression models. Treatment effects were expressed as adjusted odds ratios (aOR) with 95% CI. RESULTS: Among 231 patients, 126 (54.5%) received biologic prophylaxis and 92 (39.8%) received no treatment; endoscopy was performed in 217 patients. High-risk endoscopic recurrence occurred in 42.3% (36/85) of untreated patients compared with 9.4% (6/64) receiving tumor necrosis factor (TNF) antagonists, 27.8% (10/36) receiving ustekinumab, and 9.5% (2/21) receiving vedolizumab. After weighting for established risk factors for recurrence, all biologic strategies were associated with reduced odds of endoscopic recurrence compared with no treatment (aOR 0.15–0.31, all P < 0.05). Vedolizumab was associated with lower odds of recurrence compared with ustekinumab (aOR 0.24 [0.06–0.92], P = 0.04) but not TNF antagonists (aOR 0.43 [0.10–1.87], P = 0.26). DISCUSSION: In this real-world cohort, biologic prophylaxis is associated with reduced endoscopic recurrence in CD. Both ustekinumab and vedolizumab are effective options, including after prior TNF exposure.
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Comparative Real-World Effectiveness of Biologic Therapies for Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
BACKGROUND: Postoperative recurrence is common after ileocolonic resection for Crohn's disease (CD). Comparative effectiveness data for advanced treatments for preventing recurrence are limited. METHODS: We conducted a population-based retrospective cohort study of adults with CD undergoing ileocolonic resection with primary anastomosis in the Calgary Health Zone, Canada (2016–2020). The primary outcome was endoscopic recurrence within 18 months, assessed using the modified Rutgeerts score as an ordinal endpoint. High-risk recurrence (modified Rutgeerts score ≥ i2b) was evaluated as a secondary outcome. Propensity scores were estimated using established clinical risk factors, and inverse probability of treatment weighting targeting the average treatment effect among treated patients was applied to ordinal and logistic regression models. Treatment effects were expressed as adjusted odds ratios (aOR) with 95% CI. RESULTS: Among 231 patients, 126 (54.5%) received biologic prophylaxis and 92 (39.8%) received no treatment; endoscopy was performed in 217 patients. High-risk endoscopic recurrence occurred in 42.3% (36/85) of untreated patients compared with 9.4% (6/64) receiving tumor necrosis factor (TNF) antagonists, 27.8% (10/36) receiving ustekinumab, and 9.5% (2/21) receiving vedolizumab. After weighting for established risk factors for recurrence, all biologic strategies were associated with reduced odds of endoscopic recurrence compared with no treatment (aOR 0.15–0.31, all P < 0.05). Vedolizumab was associated with lower odds of recurrence compared with ustekinumab (aOR 0.24 [0.06–0.92], P = 0.04) but not TNF antagonists (aOR 0.43 [0.10–1.87], P = 0.26). DISCUSSION: In this real-world cohort, biologic prophylaxis is associated with reduced endoscopic recurrence in CD. Both ustekinumab and vedolizumab are effective options, including after prior TNF exposure.
- Open Access
- 19 May 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (4) , 218-224
Nationalization of clinical care pathways for inflammatory bowel disease management in Canada
Background: Inflammatory Bowel Diseases (IBD) are challenging conditions to manage due to the heterogeneity of the disease, diverse treatment options, and nuances of care over a range of ages. Clinical care pathways (CCPs) developed by experts enable health care providers (HCPs) to deliver standardized, high-quality, evidence-based care. In order to remain useful and valuable, these pathways need to evolve alongside changing treatment recommendations. Standardizing IBD care is a priority of Crohn’s Colitis Canada’s Promoting Access and Care through Centres of Excellence (PACE) network. Aim: To describe the process of nationalizing IBD CCP’s, including development, standardization, maintenance, and dissemination. Methods: This project was based on a previously developed structured framework for review and maintenance. The CCP team consisted of a leadership group, advisory council and a working group with diverse representation from the country and areas of expertise. The work was tracked with a database with coordination completed by staff of the national organization. Results: The nationalization process lasted 14 months, with input from 23 HCPs from 14 academic and community institutions across Canada. Sixteen CCPs for IBD care were developed and approved by the CCP team. Challenges encountered included outdated guidelines, differing clinical opinions, and busy clinical schedules of the team members. Translation into French is complete. Support of Crohn’s and Colitis Canada was invaluable. Conclusion: Despite anticipated challenges, 16 CCPs received approval from the advisory council and are publicly available to HCPs across Canada. Our approach to this undertaking and the lessons learned may be valuable for experts undertaking similar projects for patients with chronic diseases.
- 19 May 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (4) , 218-224
Open AccessNationalization of clinical care pathways for inflammatory bowel disease management in Canada
Background: Inflammatory Bowel Diseases (IBD) are challenging conditions to manage due to the heterogeneity of the disease, diverse treatment options, and nuances of care over a range of ages. Clinical care pathways (CCPs) developed by experts enable health care providers (HCPs) to deliver standardized, high-quality, evidence-based care. In order to remain useful and valuable, these pathways need to evolve alongside changing treatment recommendations. Standardizing IBD care is a priority of Crohn’s Colitis Canada’s Promoting Access and Care through Centres of Excellence (PACE) network. Aim: To describe the process of nationalizing IBD CCP’s, including development, standardization, maintenance, and dissemination. Methods: This project was based on a previously developed structured framework for review and maintenance. The CCP team consisted of a leadership group, advisory council and a working group with diverse representation from the country and areas of expertise. The work was tracked with a database with coordination completed by staff of the national organization. Results: The nationalization process lasted 14 months, with input from 23 HCPs from 14 academic and community institutions across Canada. Sixteen CCPs for IBD care were developed and approved by the CCP team. Challenges encountered included outdated guidelines, differing clinical opinions, and busy clinical schedules of the team members. Translation into French is complete. Support of Crohn’s and Colitis Canada was invaluable. Conclusion: Despite anticipated challenges, 16 CCPs received approval from the advisory council and are publicly available to HCPs across Canada. Our approach to this undertaking and the lessons learned may be valuable for experts undertaking similar projects for patients with chronic diseases.
- Open Access
- 10 April 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
Etrasimod-induced eosinophilia and eosinophilic gastritis
- 10 April 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
Open AccessEtrasimod-induced eosinophilia and eosinophilic gastritis
- Open Access
- 30 March 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Increased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study
Background: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes. Objectives: To evaluate the risk of rescue prednisone use following budesonide multimatrix system (MMX) initiation in newly diagnosed individuals with UC before and during the COVID-19 pandemic. Design: Population-based cohort study. Methods: We conducted a population-based study in Alberta, Canada, identifying adults with incident UC (2018–2022). Courses of budesonide MMX were examined for treatment failure, defined as prednisone rescue or inflammatory bowel disease-specific hospitalization within 90 days. Outcomes were compared between prepandemic (before April 2020) and pandemic periods using Cox proportional hazards models. Results: Among 269 dispensings of budesonide MMX (38 with multiple courses), 30.5% required rescue prednisone and 6.7% resulted in hospitalization. Budesonide MMX dispensing declined during the pandemic wherein, the hazard of prednisone rescue increased (HR 1.64; 95% CI: 1.01–2.67). Conclusion: Budesonide MMX was prescribed less frequently during the COVID-19 pandemic, with increased treatment failure, underscoring pandemic-related disruptions in UC management.
- 30 March 2026
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 19
Open AccessIncreased failure of budesonide MMX for ulcerative colitis during the COVID-19 pandemic: a population-based study
Background: Corticosteroids induce remission in ulcerative colitis (UC) but are associated with adverse effects, including prednisone ⩾20 mg/day associated with serious COVID-19 outcomes. Objectives: To evaluate the risk of rescue prednisone use following budesonide multimatrix system (MMX) initiation in newly diagnosed individuals with UC before and during the COVID-19 pandemic. Design: Population-based cohort study. Methods: We conducted a population-based study in Alberta, Canada, identifying adults with incident UC (2018–2022). Courses of budesonide MMX were examined for treatment failure, defined as prednisone rescue or inflammatory bowel disease-specific hospitalization within 90 days. Outcomes were compared between prepandemic (before April 2020) and pandemic periods using Cox proportional hazards models. Results: Among 269 dispensings of budesonide MMX (38 with multiple courses), 30.5% required rescue prednisone and 6.7% resulted in hospitalization. Budesonide MMX dispensing declined during the pandemic wherein, the hazard of prednisone rescue increased (HR 1.64; 95% CI: 1.01–2.67). Conclusion: Budesonide MMX was prescribed less frequently during the COVID-19 pandemic, with increased treatment failure, underscoring pandemic-related disruptions in UC management.
- Open Access
- 20 November 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (3) , 488-497
Association of Geography With Screening and Development of Cervical Neoplasia in Those With Inflammatory Bowel Disease
Background: While cancer risk is elevated in inflammatory bowel disease (IBD), results are less clear for cervical cancer. Screening has made cervical cancer relatively preventable, but geography impacts access, possibly increasing rates of cancer in rural and remote areas. We investigated (1) odds of cervical cancer, (2) cervical cancer screening participation, and (3) impact of geography (eg, rurality) and immunosuppression on the odds of cervical cancer and cervical cancer screening participation in the IBD population in Alberta, Canada. Methods: A population-based cohort using administrative healthcare databases (fiscal year 2003/04-2021/22) was used to identify females with IBD (n = 22 245), age- and sex-matched 10 to 1 to control subjects (n = 161 070). The average annual percent change of screening rates and incidence of cervical cancer was calculated through Poisson regression. The odds of cervical cancer were calculated with conditional logistic regression. The role of geography and immunosuppression were assessed in each analysis. Results: Individuals with IBD had lower odds of cervical cancer (odds ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83), but immunosuppressed individuals were at greater risk (odds ratio, 1.79; 95% CI, 1.48 to 2.15). Cases and controls had similar screening rates, but immunosuppressed individuals were screened more (incidence rate ratio, 1.05; 95% CI, 1.03 to 1.07). Screening declined among individuals with IBD (average annual percentage change, −5.15; 95% CI, −5.30 to −4.99), but incidence rates of cervical cancer remained stable (average annual percentage change, −1.95%; 95% CI, −4.25 to 0.41). While urban and metropolitan individuals with IBD were screened more, we observed no geographic variation in risk of cervical cancer. Conclusions: Similarities in screening between cases and controls suggest that lifestyle factors (eg, human papillomavirus vaccination, sexual history) may underpin the reduced odds of cervical cancer, rather than screening frequency. Efforts should be made to increase screening in immunosuppressed individuals.
- 20 November 2025
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 32 (3) , 488-497
Open AccessAssociation of Geography With Screening and Development of Cervical Neoplasia in Those With Inflammatory Bowel Disease
Background: While cancer risk is elevated in inflammatory bowel disease (IBD), results are less clear for cervical cancer. Screening has made cervical cancer relatively preventable, but geography impacts access, possibly increasing rates of cancer in rural and remote areas. We investigated (1) odds of cervical cancer, (2) cervical cancer screening participation, and (3) impact of geography (eg, rurality) and immunosuppression on the odds of cervical cancer and cervical cancer screening participation in the IBD population in Alberta, Canada. Methods: A population-based cohort using administrative healthcare databases (fiscal year 2003/04-2021/22) was used to identify females with IBD (n = 22 245), age- and sex-matched 10 to 1 to control subjects (n = 161 070). The average annual percent change of screening rates and incidence of cervical cancer was calculated through Poisson regression. The odds of cervical cancer were calculated with conditional logistic regression. The role of geography and immunosuppression were assessed in each analysis. Results: Individuals with IBD had lower odds of cervical cancer (odds ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83), but immunosuppressed individuals were at greater risk (odds ratio, 1.79; 95% CI, 1.48 to 2.15). Cases and controls had similar screening rates, but immunosuppressed individuals were screened more (incidence rate ratio, 1.05; 95% CI, 1.03 to 1.07). Screening declined among individuals with IBD (average annual percentage change, −5.15; 95% CI, −5.30 to −4.99), but incidence rates of cervical cancer remained stable (average annual percentage change, −1.95%; 95% CI, −4.25 to 0.41). While urban and metropolitan individuals with IBD were screened more, we observed no geographic variation in risk of cervical cancer. Conclusions: Similarities in screening between cases and controls suggest that lifestyle factors (eg, human papillomavirus vaccination, sexual history) may underpin the reduced odds of cervical cancer, rather than screening frequency. Efforts should be made to increase screening in immunosuppressed individuals.
- Open Access
- 19 November 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (6) , 267-287
Models of outpatient care delivery in inflammatory bowel disease: a scoping review
Background: As inflammatory bowel disease (IBD) becomes increasingly common worldwide, optimizing service delivery is critical to ensuring timely access to high-quality IBD care. We conducted a scoping review to understand the extent and type of evidence related to models of outpatient IBD care. Methods: We searched MEDLINE, EMBASE, CINAHL, and PsycINFO from inception to April 29, 2025 to identify English-language studies describing or evaluating models of care delivery for individuals with IBD in outpatient settings. Eligible peer-reviewed articles included publications of any type (primary studies, reviews, perspectives) focusing on any age group, timepoints in care (eg, transition from pediatric to adult care), and context (eg, remote delivery). Results: Of the 14,202 records searched, 243 met the inclusion criteria, including 89 studies evaluating models of care, 141 studies describing models of care without formal evaluation, and 13 consensus statements/guidelines. Models discussed included value-based multidisciplinary teams (with either biomedical or biopsychosocial approaches), care provided by nurses and other allied healthcare professionals (HCPs), remote monitoring and healthcare delivery, and rapid access clinics. Models increased patient satisfaction, enhanced collaboration between patients and HCPs, reduced health services utilization (eg, emergency department visits, hospitalizations), and improved patient outcomes (ie, disease activity, mental health, quality of life). Gastroenterologists, IBD nurses, and allied HCPs were consistently identified as key team members. Conclusions: Innovative outpatient models of IBD care have been proposed and evaluated. These models of care can guide modifications to IBD care globally to help address the rising demand of IBD on healthcare systems, increasing the efficiency of care.
- 19 November 2025
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 8 (6) , 267-287
Open AccessModels of outpatient care delivery in inflammatory bowel disease: a scoping review
Background: As inflammatory bowel disease (IBD) becomes increasingly common worldwide, optimizing service delivery is critical to ensuring timely access to high-quality IBD care. We conducted a scoping review to understand the extent and type of evidence related to models of outpatient IBD care. Methods: We searched MEDLINE, EMBASE, CINAHL, and PsycINFO from inception to April 29, 2025 to identify English-language studies describing or evaluating models of care delivery for individuals with IBD in outpatient settings. Eligible peer-reviewed articles included publications of any type (primary studies, reviews, perspectives) focusing on any age group, timepoints in care (eg, transition from pediatric to adult care), and context (eg, remote delivery). Results: Of the 14,202 records searched, 243 met the inclusion criteria, including 89 studies evaluating models of care, 141 studies describing models of care without formal evaluation, and 13 consensus statements/guidelines. Models discussed included value-based multidisciplinary teams (with either biomedical or biopsychosocial approaches), care provided by nurses and other allied healthcare professionals (HCPs), remote monitoring and healthcare delivery, and rapid access clinics. Models increased patient satisfaction, enhanced collaboration between patients and HCPs, reduced health services utilization (eg, emergency department visits, hospitalizations), and improved patient outcomes (ie, disease activity, mental health, quality of life). Gastroenterologists, IBD nurses, and allied HCPs were consistently identified as key team members. Conclusions: Innovative outpatient models of IBD care have been proposed and evaluated. These models of care can guide modifications to IBD care globally to help address the rising demand of IBD on healthcare systems, increasing the efficiency of care.
- 1 August 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (8)
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Background & Aims: Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods: The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results: The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
- 1 August 2025
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (8)
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Background & Aims: Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods: The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results: The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
- Open Access
- 1 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e65659
Developing and Evaluating a Bundled Digital Tool to Improve Complex Care and Self-Management of Patients With Inflammatory Bowel Disease: Protocol for a Hybrid Effectiveness-Implementation Study
Background: Individuals with inflammatory bowel disease (IBD) require comprehensive care to address the physical and psychosocial burden of their disease. The demand for IBD care often exceeds availability, resulting in delayed access and suboptimal management. As a result, patients with IBD are required to self-manage significant aspects of their disease between appointments with their medical team. Digital self-management tools may help address this gap by empowering patients to be more engaged in managing their disease, potentially improving outcomes and reducing the strain on the health care system. Objective: This study aimed to design, implement, and evaluate a bundled digital health tool, MyIBDToolkit, with the overarching goal of improving the quality of care and self-management for patients with IBD in Alberta, Canada. Methods: A bundled digital health tool, MyIBDToolkit, will be integrated into our provincial electronic health record system to ensure broad accessibility and continuity of care. We will use a type 2 hybrid effectiveness-implementation design to evaluate both the clinical impact and real-world integration of the toolkit. We will assess effectiveness through changes in key outcomes such as health care utilization (eg, emergency visits, hospitalizations), disease burden on patients (eg, quality of life, symptom control), and burden on the health care system. These outcomes will be measured using comprehensive health care administrative data. A dual-comparison approach will be used: a within-subject comparison of health care utilization and disease burden before and after implementation of the MyIBDToolkit, and a between-group comparison of outcomes among toolkit users versus nonusers. To evaluate implementation success, we will examine reach (ie, number of patients and providers using the tool), fidelity to the planned timeline, sustained use over time, and factors influencing adoption and maintenance. Our goal is to reach 10,000 patients across Alberta, Canada, within three years. Results: We received funding for this project in January 2023. In preparation for the pilot launch, we have identified key stakeholders, including patients, health care providers and, administrators, and developed strategies to assess their readiness for MyIBDToolkit. We are also collecting mixed-methods data from patients to explore potential barriers and facilitators to using MyIBDToolkit. The first phase of MyIBDToolkit was launched in October 2024. Conclusions: MyIBDToolkit represents a scalable and patient-centered approach to the self-management of IBD care. By empowering patients to self-manage their disease between health care visits, we aim to reduce the burden of IBD on patients, providers, and the health care system. By evaluating the effectiveness and the implementation of the MyIBDToolkit, we aim to generate actionable and sustainable improvements to IBD care in Alberta.
- 1 August 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e65659
Open AccessDeveloping and Evaluating a Bundled Digital Tool to Improve Complex Care and Self-Management of Patients With Inflammatory Bowel Disease: Protocol for a Hybrid Effectiveness-Implementation Study
Background: Individuals with inflammatory bowel disease (IBD) require comprehensive care to address the physical and psychosocial burden of their disease. The demand for IBD care often exceeds availability, resulting in delayed access and suboptimal management. As a result, patients with IBD are required to self-manage significant aspects of their disease between appointments with their medical team. Digital self-management tools may help address this gap by empowering patients to be more engaged in managing their disease, potentially improving outcomes and reducing the strain on the health care system. Objective: This study aimed to design, implement, and evaluate a bundled digital health tool, MyIBDToolkit, with the overarching goal of improving the quality of care and self-management for patients with IBD in Alberta, Canada. Methods: A bundled digital health tool, MyIBDToolkit, will be integrated into our provincial electronic health record system to ensure broad accessibility and continuity of care. We will use a type 2 hybrid effectiveness-implementation design to evaluate both the clinical impact and real-world integration of the toolkit. We will assess effectiveness through changes in key outcomes such as health care utilization (eg, emergency visits, hospitalizations), disease burden on patients (eg, quality of life, symptom control), and burden on the health care system. These outcomes will be measured using comprehensive health care administrative data. A dual-comparison approach will be used: a within-subject comparison of health care utilization and disease burden before and after implementation of the MyIBDToolkit, and a between-group comparison of outcomes among toolkit users versus nonusers. To evaluate implementation success, we will examine reach (ie, number of patients and providers using the tool), fidelity to the planned timeline, sustained use over time, and factors influencing adoption and maintenance. Our goal is to reach 10,000 patients across Alberta, Canada, within three years. Results: We received funding for this project in January 2023. In preparation for the pilot launch, we have identified key stakeholders, including patients, health care providers and, administrators, and developed strategies to assess their readiness for MyIBDToolkit. We are also collecting mixed-methods data from patients to explore potential barriers and facilitators to using MyIBDToolkit. The first phase of MyIBDToolkit was launched in October 2024. Conclusions: MyIBDToolkit represents a scalable and patient-centered approach to the self-management of IBD care. By empowering patients to self-manage their disease between health care visits, we aim to reduce the burden of IBD on patients, providers, and the health care system. By evaluating the effectiveness and the implementation of the MyIBDToolkit, we aim to generate actionable and sustainable improvements to IBD care in Alberta.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 18
“Simpleness”: a qualitative description study exploring patient perspectives on the barriers and facilitators of using digital health tools to self-manage inflammatory bowel disease
Background: Inflammatory bowel disease (IBD) is a chronic condition requiring lifelong management and frequent interactions with healthcare providers. Digital health tools have the potential to enhance disease management by providing real-time data and improving care coordination. Despite their potential, there is limited evidence on patient perspectives regarding barriers and facilitators to the adoption of these tools. Objectives: To explore patient perspectives on the barriers and facilitators associated with using digital health tools for IBD self-management, focusing on the adoption of a tool called MyIBDToolkit. Design: This study employed a qualitative description approach to gather detailed insights into patient experiences. Methods: Participants with a confirmed IBD diagnosis were recruited from clinics in Alberta, Canada. Data were collected via virtual semi-structured interviews conducted between June and July 2024. Thematic analysis was used to identify key themes, and member checking ensured the credibility of the findings. Results: Eighteen interviews were conducted, reaching thematic saturation. Participants viewed MyIBDToolkit as beneficial for enhancing disease monitoring and care coordination. However, concerns about data entry burden, privacy, and engagement emerged as significant barriers. Variability in healthcare provider use of the tool was another critical concern. Conclusion: While digital health tools such as MyIBDToolkit have the potential to improve IBD self-management, addressing barriers such as usability, privacy, and sustainability is crucial. Incorporating patient feedback during the design process can enhance the effectiveness and acceptability of these tools in chronic disease management.
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 18
Open Access“Simpleness”: a qualitative description study exploring patient perspectives on the barriers and facilitators of using digital health tools to self-manage inflammatory bowel disease
Background: Inflammatory bowel disease (IBD) is a chronic condition requiring lifelong management and frequent interactions with healthcare providers. Digital health tools have the potential to enhance disease management by providing real-time data and improving care coordination. Despite their potential, there is limited evidence on patient perspectives regarding barriers and facilitators to the adoption of these tools. Objectives: To explore patient perspectives on the barriers and facilitators associated with using digital health tools for IBD self-management, focusing on the adoption of a tool called MyIBDToolkit. Design: This study employed a qualitative description approach to gather detailed insights into patient experiences. Methods: Participants with a confirmed IBD diagnosis were recruited from clinics in Alberta, Canada. Data were collected via virtual semi-structured interviews conducted between June and July 2024. Thematic analysis was used to identify key themes, and member checking ensured the credibility of the findings. Results: Eighteen interviews were conducted, reaching thematic saturation. Participants viewed MyIBDToolkit as beneficial for enhancing disease monitoring and care coordination. However, concerns about data entry burden, privacy, and engagement emerged as significant barriers. Variability in healthcare provider use of the tool was another critical concern. Conclusion: While digital health tools such as MyIBDToolkit have the potential to improve IBD self-management, addressing barriers such as usability, privacy, and sustainability is crucial. Incorporating patient feedback during the design process can enhance the effectiveness and acceptability of these tools in chronic disease management.
- 31 December 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (9) , 2104-2112
Health Care Utilization of Children Born to Women With and Without Inflammatory Bowel Disease in the First 5 Years of Life: A Population-Cohort Study
INTRODUCTION: Children born to women with inflammatory bowel disease (IBD) may have increased health care utilization in early life due to genetic susceptibilities and exposure to inflammation in utero, although this has not been robustly evaluated. We aimed to characterize health care use between these groups. METHODS: We accessed province-wide health administrative databases to identify children born to women with and without IBD between 2002 and 2019. Differences in hospitalizations, emergency department visits, ambulatory visits, and endoscopy visits in the first 5 years of life were characterized. We further assessed differences in mental health-related health care utilization between groups. Multivariable negative binomial regression was performed to calculate adjusted incidence rate ratios (IRRs) with 95% confidence intervals (CIs). RESULTS: We included 17,447 and 1,832,334 children born to women with and without IBD, respectively. Compared with those born to women without IBD, children born to women with IBD appeared to have an increased rate of all-cause hospitalizations (IRR 1.06, 95% CI 1.03–1.10), all-cause emergency department visits (IRR 1.08, 95% CI 1.05–1.10), ambulatory visits (IRR 1.06, 95% CI 1.05–1.07), and endoscopic visits (IRR 2.14, 95% CI 1.70–2.69). Children born to women with IBD also seemed to have increased mental health-related ambulatory visits (IRR 1.93, 95% CI 1.01–3.76), with the most common reasons coded for these visits being neurodevelopmental/behavioral and developmental delay concerns. DISCUSSION: Children born to women with IBD may have increased health care utilization compared with those born to women without IBD.
- 31 December 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (9) , 2104-2112
Health Care Utilization of Children Born to Women With and Without Inflammatory Bowel Disease in the First 5 Years of Life: A Population-Cohort Study
INTRODUCTION: Children born to women with inflammatory bowel disease (IBD) may have increased health care utilization in early life due to genetic susceptibilities and exposure to inflammation in utero, although this has not been robustly evaluated. We aimed to characterize health care use between these groups. METHODS: We accessed province-wide health administrative databases to identify children born to women with and without IBD between 2002 and 2019. Differences in hospitalizations, emergency department visits, ambulatory visits, and endoscopy visits in the first 5 years of life were characterized. We further assessed differences in mental health-related health care utilization between groups. Multivariable negative binomial regression was performed to calculate adjusted incidence rate ratios (IRRs) with 95% confidence intervals (CIs). RESULTS: We included 17,447 and 1,832,334 children born to women with and without IBD, respectively. Compared with those born to women without IBD, children born to women with IBD appeared to have an increased rate of all-cause hospitalizations (IRR 1.06, 95% CI 1.03–1.10), all-cause emergency department visits (IRR 1.08, 95% CI 1.05–1.10), ambulatory visits (IRR 1.06, 95% CI 1.05–1.07), and endoscopic visits (IRR 2.14, 95% CI 1.70–2.69). Children born to women with IBD also seemed to have increased mental health-related ambulatory visits (IRR 1.93, 95% CI 1.01–3.76), with the most common reasons coded for these visits being neurodevelopmental/behavioral and developmental delay concerns. DISCUSSION: Children born to women with IBD may have increased health care utilization compared with those born to women without IBD.